EUCTR2006-001462-16-IT进行中（未招募）不适用
A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs. - ND
OSPEDALE POLICLINICO S. MATTEO0 个研究点目标入组 35 人开始时间: 2007年5月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-voluntary written informed consent, definite diagnosis of IM, age > 18 and < 80 years,...
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •platelet count < 100 x 10exp9/l within 14 days before enrollment, absolute neutrophil count of < 1.0 x 10 exp 9/l within 14 days before enrollment, ...
研究者
相似试验
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDRewly diagnosed Waldenstrom's macroglobulinemia (WM)MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-NLEuropean Myeloma Network90
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90
已完成
不适用
Bortezomib for children with acute lymphoblastic leukemia (ALL) without other treatment options.acute lymphoblastic leukemiarelapserefractorychildrenNL-OMON23341Erasmus MC, Rotterdam, Netherlands24
已完成
2 期
Bortezomib (Velcade®): A feasibility and phase II study in childhood relapsed acute lymphoblastic leukemiaNL-OMON35519Erasmus MC, Universitair Medisch Centrum Rotterdam4
进行中（未招募）
不适用
Bortezomib (Velcade®): a feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia - Bortezomib in relapsed Aacute lymphoblastic leukemiaMedDRA version: 12.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentEUCTR2009-014037-25-NLErasmus MC24